Proscia And Nucleai Partner To Broaden Access To AI Predictive Biomarkers
admin@pathologynews.com2024-06-25T13:59:38+00:00Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, has partnered with Nucleai, a leading spatial AI biomarker company that maps protein expression and cellular interactions within tissue samples to predict therapeutic outcomes. At the center of the collaboration, the companies will integrate Nucleai’s predictive biomarker solutions into Proscia’s Concentriq® software platform and make them available as part of Proscia’s precision medicine AI portfolio to better inform patient care.










